Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Sequencing CD20-directed bispecific antibody and CD19-directed CAR T cell therapy in large B cell lymphoma: A multicenter real-world study

Blood (2025) 146 (Supplement 1): 3663.

https://doi.org/10.1182/blood-2025-3663

Published: 2025

Journal Articles

Safety of abbreviated dose-escalation in patients (pts) receiving glofitamab (glofit) or epcoritamab (epcor)

Amanda Chron, Kelsey Baron, Ashlee Joseph, Ayushi Chauhan, Sonia Godbole, Andrew Jallouk, Amy Ayers, Ajay Major, Swetha Thiruvengadam, Narendranath Epperla, Shakthi Bhaskar, Alex Herrera, Yazeed Sawalha, Sairah Ahmed, Gilles Salles, Lorenzo Falchi, Allison Bock

Blood (2025) 146 (Supplement 1): 958.

https://doi.org/10.1182/blood-2025-958

Published: 2025

Journal Articles

Real world outcomes of sequencing bispecific antibodies (BsAb) in patients with relapsed / refractory follicular lymphoma (R/R FL): A multi-center cohort study from cubic consortium

Blood (2025) 146 (Supplement 1): 1837.

https://doi.org/10.1182/blood-2025-1837

Published: 2025

Journal Articles

Outcomes of CD20xCD3 bispecific antibody therapy in adult patients with Relapsed/Refractory transformed indolent lymphoma

Blood (2025) 146 (Supplement 1): 5521.

https://doi.org/10.1182/blood-2025-5521

Published: 2025

Journal Articles

Real-world outcomes of mosunetuzumab use in indolent and aggressive lymphomas

Blood (2025) 146 (Supplement 1): 4515.

https://doi.org/10.1182/blood-2025-4515

Published: 2025

Journal Articles

Real world efficacy of mosunetuzumab in follicular lymphoma patients previously exposed to lenalidomide: A collaborative US bispecifics consortium study

Blood (2025) 146 (Supplement 1): 5384.

https://doi.org/10.1182/blood-2025-5384

Published: 2025

Journal Articles

Prior bendamustine exposure does not compromise clinical outcomes of bispecific antibody therapy in patients with relapsed/refractory non-Hodgkin lymphoma: A cubic consortium analysis

Blood (2025) 146 (Supplement 1): 6294.

https://doi.org/10.1182/blood-2025-6294

Published: 2025

Journal Articles

Evaluation of prognostic factors and survival outcomes in patients with Relapsed/Refractory (R/R) large B-cell lymphomas (LBCLs) treated with epcoritamab

Blood (2025) 146 (Supplement 1): 3739.

https://doi.org/10.1182/blood-2025-3739

Published: 2025

Journal Articles

The impact of clonal hematopoiesis on CAR-T cell therapy outcomes: A single-center analysis

Grace Mercadante, Joseph Van Amburg, Yash Pershad, Naimisha Marneni, Jamye O'Neal, Emily F. Mason, Shakthi Bhaskar, Eden Biltibo, Vivek Patel, Reena Jayani-Kosarzycki, Bhagirathbhai Dholaria, Adetola Kassim, Michael Savona, Olalekan Oluwole, Andrew Jallouk, Alexander Bick, Ashwin Kishtagari

Blood (2025) 146 (Supplement 1): 4158.

https://doi.org/10.1182/blood-2025-4158

Published: 2025

Journal Articles

Identification of an optimal absolute lymphocyte count before bispecific antibody therapy for large B-cell lymphoma: A collaborative US bispecific consortium Study

Blood (2025) 146 (Supplement 1): 1967.

https://doi.org/10.1182/blood-2025-1967

Published: 2025

Journal Articles

Molecular and Clinical Determinants of CAR-T Therapy Response in DLBCL

Devang Thakkar, Brian T. Hill, Rachel Kositsky, Shari Tian, Leonardo Biral, Veronica Russell, Tushar Dave, Cassandra L. Love, Caroline Roth, Matthew Stuart McKinney, Ahmed Galal, Jadee Neff, Agrima Mian, Ellen Kendall, Sarah L. Ondrejka, Matthew Chiaramonte, Govind Bhagat, Kenneth N. Ofori, Ran Reshef, Alexandra E. Kovach, Tarsheen Sethi, Emily F. Mason, Shakthi Bhaskar, Olalekan O. Oluwole, Chad McCall, Christopher Pallas, Nilanjan Ghosh, Robert Ferdman, George Chen, Francisco Hernandez-Ilizaliturri, Joanna Zurko, Ashley Cunningham, Nirav C Shah, Boyu Hu, Deborah M. Stephens, Monalisa Ghosh, Neil Bailey, Krish Patel, John M. Pagel, Kavya Kannamma Kannan, Eric D. Hsi, Rakhee Vaidya, Andrew Ip, Andre Goy, Swetha Kambhampati, Robert Ohgami, Charalambos Andreadis, Christian A Gordillo, Brianna Just, Jonathon B Cohen, Arielle Baim, Julie Barbello, Erika Cavallone, Veronika Bachanova, Maureen Laschen, Andinet Teferra, Frederique Lorcy, Sylvain Lamure, Guillaume Cartron, Valerie Dardalhon, Kikkeri N Naresh, Magdalena Czader, Anupama Reddy, Elizabeth Thacker, Clayton Parker, Lanie Happ, Sandeep Dave

Blood (2024) 144 (Supplement 1): 3409.

https://doi.org/10.1182/blood-2024-199758

Published: 2024

Journal Articles

Impact of Patient Distance from Center on Outcomes and Cost of Therapy for Patients Undergoing Chimeric Antigen Receptor T-Cell Therapy for B-Cell Lymphoma

Brian Hoeynck, Shakthi Bhaskar, Andrew P Jallouk, Bhagirathbhai Dholaria, Bipin N. Savani, Olalekan O. Oluwole, David Morgan, Salyka M. Sengsayadeth, Adetola A. Kassim, Vivek Patel

Blood (2024) 144 (Supplement 1): 3663.

https://doi.org/10.1182/blood-2024-211286

Published: 2024

Journal Articles

Real-World Trends of Cytokine Release Syndrome and Neurologic Events, and Pattern of Their Management Among Patients Receiving Axicabtagene Ciloleucel for Relapsed or Refractory (r/r) Large B-Cell Lymphoma (LBCL) in the US: A CIBMTR Report

Jiasheng Wang, Shakthi Bhaskar, Babatunde Adedokun, Olalekan O. Oluwole, Leland Metheny, Amy Moskop, Caron A. Jacobson, Geoffrey Shouse, Sairah Ahmed, Armin Ghobadi, Saurabh Dahiya, Jiali Yan, Zhen-Huan Hu, Timothy Best, Jenny J. Kim, Debbie L. Mirjah, Marcelo C. Pasquini, Frederick L. Locke

Blood (2024) 144 (Supplement 1): 527.

https://doi.org/10.1182/blood-2024-209093

Published: 2024

Journal Articles

Impact of Time from Referral to Treatment on Outcomes and Cost of Therapy for Patients Undergoing Chimeric Antigen Receptor T-Cell Therapy for B-Cell Lymphoma: An Intention to Treat Analysis

Vivek Patel, Katherine Baker, Danielle Fishman, Spencer Lessans, Trent Morris, Bhagirathbhai Dholaria, Reena Jayani, Adetola A. Kassim, Tae Kon Kim, David Morgan, Olalekan O. Oluwole, Bipin N. Savani, Salyka M. Sengsayadeth, Shakthi Bhaskar

Blood (2023) 142 (Supplement 1): 5080.

https://doi.org/10.1182/blood-2023-189084

Published: 2023

Journal Articles

Patterns of Use and Impact of Post-Referral and Bridging Therapy on Outcomes in Patients Undergoing CAR T-Cell Therapy for B-Cell Lymphoma: A Single-Center Analysis

Shakthi Bhaskar, Katherine Baker, Danielle Fishman, Spencer Lessans, Bhagirathbhai Dholaria, Reena Jayani, Adetola A. Kassim, Tae Kon Kim, David Morgan, Olalekan O. Oluwole, Bipin N. Savani, Salyka Sengsayadeth, Vivek Patel

Blood (2023) 142 (Supplement 1): 6940.

https://doi.org/10.1182/blood-2023-186217

Published: 2023

Journal Articles

Flat Dose Intravenous Immunoglobulin Primary Infection Prophylaxis in Multiple Myeloma Patients on Bispecific Antibody Therapy: Vanderbilt Experience

Naimisha Marneni, Bhagirathbhai Dholaria, Salyka Sengsayadeth, Eden Ayele Biltibo, Vivek Patel, Shakthi Bhaskar, Reena Jayani, Jill Gilbert, Jordan Berlin, Ashwin Kishtagari, Sanjay Mohan, David Morgan, Olalekan O. Oluwole, Bipin N. Savani, Adetola A. Kassim, Muhamed Baljevic

Blood (2023) 142 (Supplement 1): 3778.

https://doi.org/10.1182/blood-2023-190749

Published: 2023

Journal Articles

Predictors and Outcomes of Immune Effector Cell Associated Neurotoxicity Syndrome in Patients Receiving Chimeric Antigen Receptor T-Cell Therapy for Aggressive B-Cell Non-Hodgkin Lymphoma

Vivek Patel, Shakthi Bhaskar, Stephen J. Schuster, Loretta J. Nastoupil, Miguel-Angel Perales, Roni Shouval, Joseph P. McGuirk, Richard T. Maziarz, Andy Chen, Veronika Bachanova, David L. Porter, Michael R. Bishop, Peter A. Riedell, Olalekan O. Oluwole

Blood (2022) 140 (Supplement 1): 366–368.

https://doi.org/10.1182/blood-2022-165556

Published: 2022

Journal Articles

Efficacy of CD19 Directed Therapies in Large B-Cell Lymphoma (LBCL) Relapsing after Chimeric Antigen Receptor (CAR) T-Cell Therapy

Blood (2022) 140 (Supplement 1): 10396–10398.

https://doi.org/10.1182/blood-2022-169689

Published: 2022

Journal Articles

Cytokine Release Syndrome (CRS) Is Not Required for CAR-T Cell Efficacy in Aggressive Large B-NHL

Shakthi Bhaskar, Vivek Patel, David L. Porter, Stephen J. Schuster, Loretta J. Nastoupil, Miguel-Angel Perales, Ana Alarcon Tomas, Michael R. Bishop, Joseph P. McGuirk, Richard T. Maziarz, Andy Chen, Veronika Bachanova, Peter A. Riedell, Olalekan O. Oluwole

Blood (2022) 140 (Supplement 1): 10971–10973.

https://doi.org/10.1182/blood-2022-155886

Published: 2022

Journal Articles

Impact of Molecular Features of Diffuse Large B-Cell Lymphoma on Treatment Outcomes with Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy

Blood (2021) 138 (Supplement 1): 165.

https://doi.org/10.1182/blood-2021-145764

Published: 2021

Update search

NARROW

Publications

Format

Article Type

Date

Availability

Sequencing CD20-directed bispecific antibody and CD19-directed CAR T cell therapy in large B cell lymphoma: A multicenter real-world study

Safety of abbreviated dose-escalation in patients (pts) receiving glofitamab (glofit) or epcoritamab (epcor)

Real world outcomes of sequencing bispecific antibodies (BsAb) in patients with relapsed / refractory follicular lymphoma (R/R FL): A multi-center cohort study from cubic consortium

Outcomes of CD20xCD3 bispecific antibody therapy in adult patients with Relapsed/Refractory transformed indolent lymphoma

Real-world outcomes of mosunetuzumab use in indolent and aggressive lymphomas

Real world efficacy of mosunetuzumab in follicular lymphoma patients previously exposed to lenalidomide: A collaborative US bispecifics consortium study

Prior bendamustine exposure does not compromise clinical outcomes of bispecific antibody therapy in patients with relapsed/refractory non-Hodgkin lymphoma: A cubic consortium analysis

Evaluation of prognostic factors and survival outcomes in patients with Relapsed/Refractory (R/R) large B-cell lymphomas (LBCLs) treated with epcoritamab

The impact of clonal hematopoiesis on CAR-T cell therapy outcomes: A single-center analysis

Identification of an optimal absolute lymphocyte count before bispecific antibody therapy for large B-cell lymphoma: A collaborative US bispecific consortium Study

Molecular and Clinical Determinants of CAR-T Therapy Response in DLBCL

Impact of Patient Distance from Center on Outcomes and Cost of Therapy for Patients Undergoing Chimeric Antigen Receptor T-Cell Therapy for B-Cell Lymphoma

Real-World Trends of Cytokine Release Syndrome and Neurologic Events, and Pattern of Their Management Among Patients Receiving Axicabtagene Ciloleucel for Relapsed or Refractory (r/r) Large B-Cell Lymphoma (LBCL) in the US: A CIBMTR Report

Impact of Time from Referral to Treatment on Outcomes and Cost of Therapy for Patients Undergoing Chimeric Antigen Receptor T-Cell Therapy for B-Cell Lymphoma: An Intention to Treat Analysis

Patterns of Use and Impact of Post-Referral and Bridging Therapy on Outcomes in Patients Undergoing CAR T-Cell Therapy for B-Cell Lymphoma: A Single-Center Analysis

Flat Dose Intravenous Immunoglobulin Primary Infection Prophylaxis in Multiple Myeloma Patients on Bispecific Antibody Therapy: Vanderbilt Experience

Predictors and Outcomes of Immune Effector Cell Associated Neurotoxicity Syndrome in Patients Receiving Chimeric Antigen Receptor T-Cell Therapy for Aggressive B-Cell Non-Hodgkin Lymphoma

Efficacy of CD19 Directed Therapies in Large B-Cell Lymphoma (LBCL) Relapsing after Chimeric Antigen Receptor (CAR) T-Cell Therapy

Cytokine Release Syndrome (CRS) Is Not Required for CAR-T Cell Efficacy in Aggressive Large B-NHL

Impact of Molecular Features of Diffuse Large B-Cell Lymphoma on Treatment Outcomes with Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only